Patent · US Active

[6R]—MTHF—an efficient folate alternative in 5-fluorouracil based chemotherapy

US11013744B2 · kind B2 · utility

0Cited by

4References

15Claims

0Family size

Assignee

Isofol Medical AB · SE

Inventors

Per L. Lindberg · Mölndal, SE
Anders Vedin · Göteborg, SE
Gunnel E. Sunden · Göteborg, SE
Bengt Gustavsson · Mörbylånga, SE

Key dates

Filing date	Jan 9, 2018
Grant date	May 25, 2021
Priority date	—
Expiry date	May 9, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K16/22
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to the treatment of solid tumors in humans such as cancer, especially colorectal cancer (CRC), which involves administering the diastereomerically pure folate adjuvant [6R]-5,10-methylenetetrahydrofolate in 5-fluorouracil (5-FU) based chemotherapy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.